A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: Common downstream endpoints achieved through disparate therapeutic approaches?

American Journal of Nephrology

Volumn 30, Issue 4, 2009, Pages 323-335

  Sourris, Karly C ^a   Harcourt, Brooke E ^a,b   Forbes, Josephine M ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Advanced glycation end products; Diabetic nephropathy; Reactive oxygen species; Receptor for advanced glycation end products

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 N CARBOXYMETHYLLYSINE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; AMINOGUANIDINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENFOTIAMINE; CARNOSINE; CONNECTIVE TISSUE GROWTH FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTOSIDINE; PROTEIN KINASE C; PYRIDOXAMINE; REACTIVE OXYGEN METABOLITE; THIAMINE; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG INHIBITION; DRUG PROTEIN BINDING; GLYCATION; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MICROALBUMINURIA; MICROANGIOPATHY; PATHOGENESIS; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW;

DIABETIC NEPHROPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPOGLYCEMIC AGENTS; MICROCIRCULATION; REACTIVE OXYGEN SPECIES; TEPROTIDE; VITAMINS;

EID: 67649234171     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000226586     Document Type: Review

References (182)

1. Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, Bassal S, El-Osta A, Long DM, Panagiotopoulos S, Jerums G, Osicka TM, Cooper ME: Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005; 16: 2363-2372. (Pubitemid 41725054)
2. Cooper ME: Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957-1972.
3. Forbes JM, Fukami K, Cooper ME: Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 2007; 115: 69-84. (Pubitemid 46408113)
4. Thomas MC, Tikellis C, Burns WM, Bialkowski K, Cao Z, Coughlan MT, Jandeleit- Dahm K, Cooper ME, Forbes JM: Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005; 16: 2976-2984. (Pubitemid 44743495)
5. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713. (Pubitemid 28414300)
6. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-2569. (Pubitemid 34517203)
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
8. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR: Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986; 314: 403-408. (Pubitemid 16161885)
9. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997; 94: 6474-6479. (Pubitemid 27270709)
10. Vlassara H, Palace MR: Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
11. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S: Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial Diabetes 1999; 48: 870-880.
12. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM: Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51: 3274-3282. (Pubitemid 35246974)
13. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K: Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478-2487.
14. Marx N, Walcher D, Ivanova N, Rautzenberg K, Jung A, Friedl R, Hombach V, de Caterina R, Basta G, Wautier MP, Wautiers JL: Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004; 53: 2662-2668. (Pubitemid 39299276)
15. Urios P, Grigorova-Borsos AM, Sternberg M: Aspirin inhibits the formation of pentosidine, a cross-linking advanced glycation end product, in collagen. Diabetes Res Clin Pract 2007; 77: 337-340. (Pubitemid 46670425)
16. Yan H, Guo Y, Zhang J, Ding Z, Ha W, Harding JJ: Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats. Mol Vis 2008; 14: 2282-2291.
17. Jyothirmayi GN, Soni BJ, Masurekar M, Lyons M, Regan TJ: Effects of metformin on collagen glycation and diastolic dysfunction in diabetic myocardium. J Cardiovasc Pharmacol Ther 1998; 3: 319-326. (Pubitemid 29131662)
18. Beisswenger P, Ruggiero-Lopez D: Metformin inhibition of glycation processes. Diabetes Metab 2003; 29: 6S95-6S103.
19. O'Brien T, Nguyen TT, Zimmerman BR: Hyperlipidemia and diabetes mellitus. Mayo Clin Proc 1998; 73: 969-976.
20. Chait A, Beirman EL: Joslin's Diabetes Mellitus. Philadelphia, Lea & Febiger, 1994.
21. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412.
22. Bierhaus A, Schiekofer S, Schwaninger M, et al: Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50: 2792-2808. (Pubitemid 33733131)
23. Lin L: RAGE on the toll road? Cell Mol Immunol 2006; 3: 351-358.
24. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL: Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997; 100: 115-126. (Pubitemid 27311249)
25. Maillard L: Action des acides amines sur les sucres: formation des mélanoidines par voie méthodique. CR Acad Sci 1912; 154: 66-68.
26. Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM: Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 1992; 41: 1286-1292.
27. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294-2303. (Pubitemid 36638103)
28. Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, Van Ypersele de Strihou C, Kurokawa K: Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol 1998; 9: 1681-1688. (Pubitemid 28405076)
29. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-2167.
30. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9. (Pubitemid 29019345)
31. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ: Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110-2120. (Pubitemid 36919806)
32. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 1995; 38: 387-394.
33. Stitt A, Gardiner TA, Anderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR: The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51: 2826-2832. (Pubitemid 34970937)
34. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ: Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006; 29: 2654-2659. (Pubitemid 44912194)
35. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM: Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005; 54: 3103-3111. (Pubitemid 43334362)
36. Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam B, Murray-McIntosh RP, Cooper ME: Advanced glycation end products and the receptor for advanced glycated end products co-localise in organs susceptible to diabetic microvascular injury: immunohistochemical studies. Diabetologia 1997; 40: 619-628.
37. Makita Z, Bucala R, Rayfield EJ, et al: Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343: 1519-1522. (Pubitemid 24180047)
38. Miura J, Yamagishi S, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y: Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diab Compl 2003; 17: 16-21. (Pubitemid 36042787)
39. Kalousova M, Hodkova M, Kazderova M, Fialova J, Tesar V, Dusilova-Sulkova S, Zima T: Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006; 47: 406-411. (Pubitemid 43255173)
40. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842.
41. Wautier MP, Massin P, Guillausseau PJ, Huijberts M, Levy B, Boulanger E, Laloi-Michelin M, Wautier JL: N(carboxymethyl) lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab 2003; 29: 44-52. (Pubitemid 36362615)
42. Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, Brownlee M, Hanssen KF: Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 2003; 52: 163-167. (Pubitemid 36388837)
43. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H: Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995; 44: 824-829.
44. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-15004.
45. Li Y, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, He C, Banerjee D, Vlassara H: Molecular identity and distribution of advanced glycation endproducts receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 1996; 93: 11047-11052. (Pubitemid 26333115)
46. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A: Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995; 1: 634-646.
47. Ohgami N, Nagai R, Ikemoto M, Arai H, Kuniyasu A, Horiuchi S, Nakayama H: Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem 2001; 276: 3195-3202. (Pubitemid 37411612)
48. Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T, Takahashi K, Shichiri M, Horiuchi S: Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem 1995; 230: 408-415.
49. Takata K, Horiuchi S, Araki N, Shiga M, Saitoh M, Morino Y: Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J Biol Chem 1988; 263: 14819-14825. (Pubitemid 18251915)
50. Chou SM, Han CY, Wang HS, Vlassara H, Bucala R: A receptor for advanced glycosylation endproducts (AGEs) is colocalized with neurofilament-bound AGEs and SOD1 in motoneurons of ALS: immunohistochemical study. J Neurol Sci 1999; 169: 87-92. (Pubitemid 29502513)
51. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H: Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991; 174: 931-939.
52. Vlassara H, Moldawer L, Chan B: Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor. J Clin Invest 1989; 84: 1813-1820. (Pubitemid 20016185)
53. Vlassara H: The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001; 17: 436-443.
54. Yang Z, Makita Z, Horii Y, Brunelle S, Cerami A, Sehajpal P, Suthanthiran M, Vlassara H: Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med 1991; 174: 515-524.
55. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-1334.
56. Miyata T, Ueda Y, Asahi K, Izuhara Y, Inagi R, Saito A, Van Ypersele De Strihou C, Kurokawa K: Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol 2000; 11: 1719-1725. (Pubitemid 30679721)
57. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 1986; 232: 1629-1632. (Pubitemid 16095602)
58. Khalifah RG, Chen Y, Wassenberg JJ: Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. Ann NY Acad Sci 2005; 1043: 793-806. (Pubitemid 41123974)
59. Booth AA, Khalifah RG, Todd P, Hudson BG: In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs): novel inhibition of post-Amadori glycation pathways. J Biol Chem 1997; 272: 5430-5437.
60. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS: Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 1999; 48: 198-202. (Pubitemid 29019373)
61. Brenner BM, Cooper ME, de Zeeuw D, Grunfeld JP, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving HH, Remuzzi G, Ribeiro AB, Schluchter MD, Snavely D, Zhang Z, Simpson R, Ramjit D, Shahinfar S: The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000; 1: 328-335.
62. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, Ishikawa N, Yuzawa H, Koike H, van Ypersele de Strihou C, Kurokawa K: Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14: 1212-1222. (Pubitemid 36514663)
63. Forbes JM, Thomas MC, Thorpe SR, Alderson NL, Cooper ME: The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney Int Suppl 2004; 92: S105-S107. (Pubitemid 43361443)
64. Figarola JL, Loera S, Weng Y, Shanmugam N, Natarajan R, Rahbar S: LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia 2008; 51: 882-891.
65. Figarola JL, Scott S, Loera S, Tessler C, Chu P, Weiss L, Hardy J, Rahbar S: LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 2003; 46: 1140-1152. (Pubitemid 37041245)
66. Chetyrkin SV, Zhang W, Hudson BG, Serianni AS, Voziyan PA: Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine. Biochemistry 2008; 47: 997-1006.
67. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-950.
68. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB: Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007; 27: 605-614.
69. Berrone E, Beltramo E, Solimine C, Ape AU, Porta M: Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006; 281: 9307-9313. (Pubitemid 43864646)
70. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley PJ: Accumulation of fructosyllysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans 2003; 31: 1423-1425. (Pubitemid 38030991)
71. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D: Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006; 29: 2064-2071. (Pubitemid 44871188)
72. Du X, Edelstein D, Brownlee M: Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 2008; 51: 1930-1932.
73. Alhamdani MS, Al-Azzawie HF, Abbas FK: Decreased formation of advanced glycation end-products in peritoneal fluid by carnosine and related peptides. Perit Dial Int 2007; 27: 86-89.
74. Alhamdani MS, Al-Kassir AH, Abbas FK, Jaleel NA, Al-Taee MF: Antiglycation and antioxidant effect of carnosine against glucose degradation products in peritoneal mesothelial cells. Nephron Clin Pract 2007; 107: c26-c34.
75. Hipkiss AR, Preston JE, Himsworth DT, Worthington VC, Keown M, Michaelis J, Lawrence J, Mateen A, Allende L, Eagles PA, Abbott NJ: Pluripotent protective effects of carnosine, a naturally occurring dipeptide. Ann NY Acad Sci 1998; 854: 37-53.
76. Hipkiss AR, Chana H: Carnosine protects proteins against methylglyoxal-mediated modifications. Biochem Biophys Res Commun 1998; 248: 28-32.
77. Janssen B, Hohenadel D, Brinkkoetter P, et al: Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 2005; 54: 2320-2327. (Pubitemid 41134258)
78. Vasan S, Zhang X, Zhang X, et al: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996; 382: 275-278. (Pubitemid 26251366)
79. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME: The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. Faseb J 2003; 17: 1762-1764.
80. Cooper ME, Thallas V, Forbes J, Scalbert E, Sastra S, Darby I, Soulis T: The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 2000; 43: 660-664.
81. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005; 11: 191-195.
82. Kislinger T, Fu C, Huber B, et al: N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274: 31740-31749. (Pubitemid 129501639)
83. Yamamoto Y, Kato I, Doi T, et al: Development and prevention of advanced diabetic nephropathy in RAGE- overexpressing mice. J Clin Invest 2001; 108: 261-268. (Pubitemid 32656250)
84. Yonekura H, Yamamoto Y, Sakurai S, et al: Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370: 1097-1109. (Pubitemid 36399105)
85. Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, Nawroth PP, Bierhaus A, Postina R: Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 2008; 283: 35507-35516.
86. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME: A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008; 22: 3716-3727.
87. Sakurai S, Yamamoto Y, Tamei H, et al: Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 2006; 73: 158-165. (Pubitemid 43928158)
88. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ: Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006; 49: 2756-2762.
89. Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T: Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev 2008; 24: 109-114. (Pubitemid 351284754)
90. Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T: Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 2008; 76: 52-56.
91. Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, Bierhaus A: Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007; 6: 9. (Pubitemid 46443939)
92. Wendt TM, Tanji N, Guo J, et al: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-1137. (Pubitemid 36350658)
93. Wang K, Zhou Z, Zhang M, Fan L, Forudi F, Zhou X, Qu W, Lincoff AM, Schmidt AM, Topol EJ, Penn MS: Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 2006; 317: 37-43.
94. Hirasawa Y, Matsui Y, Yamane K, Yabuki SY, Kawasaki Y, Toyoshi T, Kyuki K, Ito M, Sakai T, Nagamatsu T: Pioglitazone improves obesity type diabetic nephropathy: relation to the mitigation of renal oxidative reaction. Exp Anim 2008; 57: 423-432.
95. Tan KC, Chow WS, Tso AW, Xu A, Tse HF, Hoo RL, Betteridge DJ, Lam KS: Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 2007; 50: 1819-1825. (Pubitemid 47222871)
96. Dragomir E, Tircol M, Manduteanu I, Voinea M, Simionescu M: Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells. Vascul Pharmacol 2006; 44: 440-449. (Pubitemid 44235955)
97. Makino H, Mukoyama M, Sugawara A, Mori K, Suganami T, Yahata K, Fujinaga Y, Yokoi H, Tanaka I, Nakao K: Roles of connective tissue growth factor and prostanoids in early streptozotocin-induced diabetic rat kidney: the effect of aspirin treatment. Clin Exp Nephrol 2003; 7: 33-40. (Pubitemid 36460539)
98. Odetti P, Traverso N, Cosso L, Noberasco G, Pronzato MA, Marinari UM: Good glycaemic control reduces oxidation and glycation end-products in collagen of diabetic rats. Diabetologia 1996; 39: 1440-1447. (Pubitemid 26397348)
99. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993; 16: 621-629.
100. Derosa G, Dangelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Cicero AF: Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J Int Med Res 2006; 34: 545-555. (Pubitemid 44756143)
101. Zhang JZ, Gao L, Widness M, Xi X, Kern TS: Captopril inhibits glucose accumulation in retinal cells in diabetes. Invest Ophthalmol Vis Sci 2003; 44: 4001-4005. (Pubitemid 37047975)
102. Matsumoto M, Tanimoto M, Gohda T, Aoki T, Murakoshi M, Yamada K, Yamazaki T, Kaneko S, Horikoshi S, Tomino Y: Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-Ay/Ta mice. Metabolism 2008; 57: 691-697. (Pubitemid 351608231)
103. Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P, Atzeni MM, Melis MG, Maioli M: Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997; 20: 1891-1895. (Pubitemid 27522902)
104. Fujii M, Inoguchi T, Maeda Y, Sasaki S, Sawada F, Saito R, Kobayashi K, Sumimoto H, Takayanagi R: Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney Int 2007; 72: 473-480. (Pubitemid 47237615)
105. Lee YT, Hsu CC, Lin MH, Liu KS, Yin MC: Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. Eur J Pharmacol 2005; 513: 145-150.
106. Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H, Cooper ME, Forbes JM: Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 2004; 53: 2921-2930. (Pubitemid 39425918)
107. Hoang A, Murphy AJ, Coughlan MT, Thomas MC, Forbes JM, O'Brien R, Cooper ME, Chin-Dusting JP, Sviridov D: Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 2007; 50: 1770-1779. (Pubitemid 47036662)
108. Nobecourt E, Zeng J, Davies MJ, Brown BE, Yadav S, Barter PJ, Rye KA: Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I. Diabetologia 2008; 51: 1008-1017.
109. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869. (Pubitemid 34940825)
110. Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, Motomiya Y, Bucala R, Iida S, Tamaki K, Imaizumi T, Cooper ME, Okuda S: AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004; 66: 2137-2147. (Pubitemid 41115277)
111. Coughlan MT, Thallas-Bonke V, Pete J, Long DM, Gasser A, Tong DC, Arnstein M, Thorpe SR, Cooper ME, Forbes JM: Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 2007; 148: 886-895.
112. Mizutani K, Ikeda K, Tsuda K, Yamori Y: Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats. J Hypertens 2002; 20: 1607-1614. (Pubitemid 34921185)
113. Price DL, Rhett PM, Thorpe SR, Baynes JW: Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001; 276: 48967-48972. (Pubitemid 37370599)
114. Forbes JM, Coughlan MT, Cooper ME: Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446-1454.
115. Endo N, Nishiyama K, Okabe M, Matsumoto M, Kanouchi H, Oka T: Vitamin B6 suppresses apoptosis of NM-1 bovine endothelial cells induced by homocysteine and copper. Biochim Biophys Acta 2007; 1770: 571-577. (Pubitemid 46281455)
116. Hammes HP, Du X, Edelstein D, et al: Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-299. (Pubitemid 36362784)
117. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler JL: Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000; 301: 65-77. (Pubitemid 30742550)
118. Wada R, Nishizawa Y, Yagihashi N, Takeuchi M, Ishikawa Y, Yasumura K, Nakano M, Yagihashi S: Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 2001; 31: 513-520. (Pubitemid 32579388)
119. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM: Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238-243. (Pubitemid 26021714)
120. + )-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic Biol Med 2001; 30: 232-237.
121. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI, Brownlee M, Monnier VM, Weiss MF: Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 2005; 289:F420-F430. (Pubitemid 41003672)
122. Dragomir E, Manduteanu I, Voinea M, Costache G, Manea A, Simionescu M: Aspirin rectifies calcium homeostasis, decreases reactive oxygen species, and increases NO production in high glucose-exposed human endothelial cells. J Diabetes Complications 2004; 18: 289-299. (Pubitemid 39165436)
123. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL: Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992; 89: 11059-11063.
124. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL: Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994; 43: 1122-1129. (Pubitemid 24265474)
125. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000; 14: 439-447. (Pubitemid 30143162)
126. Meier M, Park JK, Boehn M, Elger M, Leitges M, Haller H, Menne J: Knockout of protein kinase C alpha protect against the development of albuminuria but not renal hypertrophy. Diabetes, in press, accepted 10th December, 2003.
127. Osicka TM, Yu YX, Panagiotopoulos S, Clavant SP, Kiriazis Z, Pike RN, Pratt LM, Russo LM, Kemp BE, Comper WD, Jerums G: Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 2000; 49: 87-93. (Pubitemid 30022928)
128. Osicka TM, Yu Y, Lee V, Panagiotopoulos S, Kemp BE, Jerums G: Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. Clin Sci (Colch) 2001; 100: 249-257. (Pubitemid 32215995)
129. Malhotra A, Reich D, Nakouzi A, Sanghi V, Geenen DL, Buttrick PM: Experimental diabetes is associated with functional activation of protein kinase C epsilon and phosphorylation of troponin I in the heart, which are prevented by angiotensin II receptor blockade. Circ Res 1997; 81: 1027-1033. (Pubitemid 27514953)
130. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schonbeck U, Libby P: Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006; 26: 611-617.
131. Barnes PJ, Larin M: Mechanisms of disease - nuclear factor-kappa-B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
132. Pieper GM, Riaz-ul-Haq: Activation of nuclear factor-kappa-B in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. J Cardiovasc Pharmacol 1997; 30: 528-532.
133. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790. (Pubitemid 30212409)
134. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897. (Pubitemid 24196599)
135. Ruiz-Ortega M, Lorenzo O, Egido J: Angiotensin III increases MCP-1 and activates NF-kappaB and AP-1 in cultured mesangial and mononuclear cells. Kidney Int 2000; 57: 2285-2298. (Pubitemid 30340728)
136. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J: Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000; 86: 1266-1272.
137. Lee FT, Cao Z, Long DM, Panagiotopoulos S, Jerums G, Cooper ME, Forbes JM: Interactions between angiotensin II and NF-{kappa}B-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol 2004; 15: 2139-2151. (Pubitemid 39031352)
138. Rangan GK, Wang YP, Tay YC, Harris DCH: Inhibition of nuclear factor-kappa B activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int 1999; 56: 118-134.
139. Liu HQ, Wei XB, Sun R, Cai YW, Lou HY, Wang JW, Chen AF, Zhang XM: Angiotensin II stimulates intercellular adhesion molecule-1 via an AT1 receptor/nuclear factor-kappaB pathway in brain microvascular endothelial cells. Life Sci 2006; 78: 1293-1298. (Pubitemid 43199949)
140. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS: Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 2007; 56: 337-345. (Pubitemid 46263071)
141. Odashima M, Otaka M, Jin M, Wada I, Horikawa Y, Matsuhashi T, Ohba R, Hatakeyama N, Oyake J, Watanabe S: Zinc L -carnosine protects colonic mucosal injury through induction of heat shock protein 72 and suppression of NF-kappaB activation. Life Sci 2006; 79: 2245-2250. (Pubitemid 44666062)
142. Ninichuk V, Khandoga AG, Segerer S, et al: The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am J Pathol 2007; 170: 1267-1276. (Pubitemid 47339334)
143. Wu CH, Huang CM, Lin CH, Ho YS, Chen CM, Lee HM: Advanced glycosylation end products induce NF-kappaB dependent iNOS expression in RAW 264.7 cells. Mol Cell Endocrinol 2002; 194: 9-17.
144. Hohenstein B, Hugo CP, Hausknecht B, Boehmer KP, Riess RH, Schmieder RE: Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrol Dial Transplant 2008; 23: 1346-1354. (Pubitemid 351767511)
145. Nguyen D, Ping F, Mu W, Hill P, Atkins RC, Chadban SJ: Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton) 2006; 11: 226-231. (Pubitemid 43829442)
146. Giunti S, Tesch GH, Pinach S, Burt DJ, Cooper ME, Cavallo-Perin P, Camussi G, Gruden G: Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 2008; 51: 198-207. (Pubitemid 350197986)
147. Chow FY, Nikolic-Paterson DJ, Ma FY, Ozols E, Rollins BJ, Tesch GH: Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007; 50: 471-480.
148. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH: Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004; 65: 116-128. (Pubitemid 38037496)
149. Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH: Macrophages in streptozotocin-nduced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant 2004; 19: 2987-2996. (Pubitemid 40057619)
150. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH: Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006; 69: 73-80. (Pubitemid 43117741)
151. Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219. (Pubitemid 28327814)
152. Tesch GH: MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008; 294:F697-F701.
153. Matsui T, Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, Inoue H: Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 2007; 35: 482-489. (Pubitemid 47261110)
154. Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, Takahashi T, Abe H, Iehara N, Fukatsu A, Okamoto H, Kita T, Doi T, Arai H: Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 2007; 360: 772-777. (Pubitemid 47077388)
155. Wang QY, Chen FQ: Clinical significance and different levels of urinary monocyte chemoattractant protein-1 in type 2 diabetes mellitus. Diabetes Res Clin Pract 2009; 83: 215-219.
156. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME, Jandeleit-Dahm KA: Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 2004; 109: 1536-1542. (Pubitemid 38420183)
157. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME: Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001; 12: 2098-2107. (Pubitemid 32880346)
158. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC: Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008; 105: 15896-15901.
159. Gu L, Hagiwara S, Fan Q, Tanimoto M, Kobata M, Yamashita M, Nishitani T, Gohda T, Ni Z, Qian J, Horikoshi S, Tomino Y: Role of receptor for advanced glycation end-roducts and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006; 21: 299-313. (Pubitemid 43159982)
160. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J: Mechanism of activation of the TGF-beta receptor. Nature 1994; 370: 341-347.
161. Massague J: TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-791.
162. Gruden G, Thomas S, Burt D, Zhou W, Chusney G, Gnudi L, Viberti G: Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol 1999; 10: 730-737. (Pubitemid 29149522)
163. Jandeleit-Dahm K, Cao Z, Cox AJ, Kelly DJ, Gilbert RE, Cooper ME: Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int Suppl 1999; 71:S31-S36. (Pubitemid 29304809)
164. Rocco MV, Neilson EG, Hoyer JR, Ziyadeh FN: Attenuated expression of epithelial cell adhesion molecules in murine polycystic kidney disease. Am J Physiol 1992; 262: F679-F686.
165. Wolf G, Ziyadeh FN, Zahner G, Stahl RA: Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells: attenuation after stable transfection with the c-mas oncogene. Kidney Int 1995; 48: 1818-1827.
166. Montero A, Munger KA, Khan RZ, Valdivielso JM, Morrow JD, Guasch A, Ziyadeh FN, Badr KF: F(2)-isoprostanes mediate high glucose-induced TGF-beta synthesis and glomerular proteinuria in experimental type I diabetes. Kidney Int 2000; 58: 1963-1972.
167. Herman WH, Emancipator SN, Rhoten RL, Simonson MS: Vascular and glomerular expression of endothelin-1 in normal human kidney. Am J Physiol 1998; 275:F8-F17. (Pubitemid 28376328)
168. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015-8020. (Pubitemid 30460765)
169. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996; 45: 522-530. (Pubitemid 26110260)
170. Hill C, Flyvbjerg A, Grønbaek H, Petrik J, Hill DJ, Thomas CR, Sheppard MC, Logan A: The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology 2000; 141: 1196-1208. (Pubitemid 32260463)
171. Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME: Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin Sci (Lond) 2001; 100: 591-599. (Pubitemid 32523310)
172. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G, Cooper ME: Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001; 44: 108-114. (Pubitemid 32141892)
173. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000; 11: 25-38. (Pubitemid 30020423)
174. Twigg SM, Cao Z, McLennan SV, Burns WC, Brammar G, Forbes JM, Cooper ME: Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002; 143: 4907-4915. (Pubitemid 35397630)
175. Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, Brady HR: Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 1999; 274: 5830-5834. (Pubitemid 29109239)
176. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R: Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998; 53: 853-861. (Pubitemid 28155657)
177. Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, Oh Y, Rosenfeld RG: Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 2001; 142: 1760-1769. (Pubitemid 32405931)
178. Rizkalla B, Forbes JM, Cooper ME, Cao Z: Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol 2003; 14: 3061-3071. (Pubitemid 37509284)
179. De Vriese AS, Tilton RG, Stephan CC, Lameire NH: Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 2001; 12: 1734-1741. (Pubitemid 32674437)
180. Advani A, Kelly DJ, Advani SL, Cox AJ, Thai K, Zhang Y, White KE, Gow RM, Marshall SM, Steer BM, Marsden PA, Rakoczy PE, Gilbert RE: Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci USA 2007; 104: 14448-14453. (Pubitemid 350003281)
181. Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, Chen S: Blockade of vascular endothelial growth factor signalling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17: 3093-3104. (Pubitemid 44707769)
182. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K, Koike T: Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999; 42: 579-588. (Pubitemid 29196009)